Why the study?
Does single antiplatelet therapy improve outcomes or reduce bleeding compared to dual antiplatelet therapy in very elderly, medically managed patients with acute myocardial infarction?
Does single antiplatelet therapy improve outcomes or reduce bleeding compared to dual antiplatelet therapy in very elderly, medically managed patients with acute myocardial infarction?
In very elderly patients medically managed for AMI, aspirin alone provides comparable protective effects to DAPT, whereas clopidogrel alone is associated with higher all-cause mortality.
Answers are grounded in this paper and cite their sources.
Aspirin monotherapy may be comparable to DAPT in very elderly medically managed AMI; leaves open optimal regimen and requires prospective confirmation.
BACKGROUNDS: To examine the comparative effectiveness between dual and single antiplatelet therapies in real-world, medically managed elderly patients with acute myocardial infarction (AMI). METHODS: This retrospective study identified very elderly (> 85 years) patients, who were medically managed, with their first AMI from the Taiwan National Health Insurance claims database from 2007 to 2010. Patients were classified as dual antiplatelet therapy (DAPT) group, aspirin only group and clopidogrel only group. Study outcomes included all-cause death, cardiovascular death and gastrointestinal bleeding. Treating DAPT group as the reference, we employed a multivariable Cox regression model to compare the relative risks of outcomes between 3 groups using pairwise comparison approach. RESULTS: Among 1469 patients with incident ST-elevation myocardial infarction (STEMI, 14%) or non-STEMI (86%), 390 patients were prescribed DAPT, 549 aspirin only, and 530 clopidogrel only. After 9 months of follow-up, aspirin only group had similar risks of all-cause death (adjusted HR 1.21, 95% CI 0.77-1.89, p = 0.41), cardiovascular death (adjusted HR 1.16, 95% CI 0.66-2.04, p = 0.60) and gastrointestinal bleeding (adjusted HR 1.66, 95% CI 0.77-3.57, p = 0.20) in comparison with DAPT group. Clopidogrel users had a higher risk of all-cause death (adjusted HR 1.50, 95% CI 1.00-2.25, p = 0.049) but similar risks of cardiovascular death and gastrointestinal bleeding when compared with DAPT. CONCLUSIONS: Among very elderly patients who were medically managed after AMI, single antiplatelet therapy had comparable protective effect as DAPT. But clopidogrel only strategy was associated with a higher risk of all-cause death.
No takes yet. Share an insight, caveat, or question.
Lin et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: